| Ref number |
Authors |
Candidates medications |
Report |
| |
Year published |
|
style |
| 38 |
Fujimori S (2011) |
Rebamipide |
CS |
| 39 |
Mizukami K (2011) |
Rebamipide |
CS |
| 37 |
Kurokawa S (2013) |
Rebamipide |
CS |
| 40 |
Fujimori S (2010) |
Rebamipide and misoprostol |
CS |
| 41 |
Watanabe T (2008) |
misoprostol |
CS |
| 43 |
Arakawa T (2012) |
prostaglandin derivatives, mucoprotective drugs, probiotics, and mitochondrial protective drugs |
A |
| 42 |
Takeuchi K (2010) |
Endogenous PGE(2) |
A |
| 45 |
Higuchi K (2009) |
Lansoprazole |
A |
| 44 |
Yoda Y (2010) |
Lansoprazole |
A |
| 47 |
Lim YJ (2012) |
PPIs: no small bowel protective effect |
A |
| 46 |
Zhang S (2013) |
Omeprazole and pantoprazole cannot protect the small intestine from the damage induced by diclofenac |
A |
| 48 |
Amagase K (2010) |
Lafutidine (histamine H(2) receptor antagonist with a mucosal protective action) |
A |
| 49 |
Umegaki E (2010) |
Roxatidine (H(2) receptor antagonist) |
A |
| 50 |
Satoh H (2012) |
Inhibition of acid secretion by antisecretory drugs may exacerbate NSAID-induced intestinal lesions |
A |
| 51 |
Guslandi M (2012) |
probiotics |
CS |
| 52 |
Satoh H (2010) |
Soluble dietary fibers |
A |
| 53 |
Satoh H (2010) |
Insoluble dietary fiber and soluble dietary fiber |
A |
| 54 |
Sivalingam N (2011) |
Zinc |
A |
| 55 |
Rodríguez de la Serna A (1994) |
Zinc acexamate |
CS |
| 57 |
Wallace JL (1994) |
NO-releasing NSAID |
A |
| 56 |
Takeuchi K (2007) |
Endogenous NO |
A |
| 3 |
Lim YJ (2012) |
Selective COX-2 inhibitors (coxibs) |
A |
| 58 |
Maehata Y (2012) |
Selective COX-2 inhibitors are not completely safe for the small bowel |
CS |
| 59 |
Fukumoto K (2011) |
TNF-α |
A |
| 60 |
LoGuidice A (2012) |
bacterial β-D-glucuronidase |
A |
| 61 |
LoGuidice A (2010) |
Mitochondrial cyclophilin D |
A |
| 62 |
Kawahara R (2011) |
α7 nicotinic acetylcholine receptors |
A |
| 63 |
Shiotani A (2010) |
geranylgeranylacetone |
CS |
| 64 |
Iwai T (2011) |
Geranylgeranylacetone |
A |
| 33 |
Higashiyama M (2012) |
cilostazol (specific phosphodiesterase (PDE)-3 inhibitor) |
A |
| 65 |
Kato N (2009) |
Sildenafil (inhibitor of phosphodiesterase subtype 5) |
A |
| 66 |
Yasuda M (2011) |
Dopamine D2-receptor antagonists |
A |
| 67 |
Yanaka A (2013) |
Sulforaphane |
CL |
| 68 |
Menozzi A (2010) |
K(ATP) channel opener diazoxide |
A |
| 69 |
Marchbank T (2008) |
Natural bioactive products (nutriceuticals), such as fish hydrolysates |
CS |
| 70 |
Amagase K (2012) |
Monosodium glutamate |
A |
| 71 |
Chao G (2012) |
Muscovite (natural clay consisting of an insoluble double silicate of aluminum and magnesium) diclofenac |
A |
| 72 |
Davies NM (1997) |
tempo (nitroxide stable free radical scavenger) and metronidazole |
A |
Abbreviations